Targeting and Treating Cancer
|
|
- Howard Douglas
- 5 years ago
- Views:
Transcription
1 Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies 2016
2 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future events. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and results of clinical trials and other development activities; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this presentation as of its date and does not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise. Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after the date of this presentation. This presentation may not be copied or reproduced in any manner or medium. 2
3 PROGENICS: TARGETING AND TREATING CANCER Building an oncology company with a portfolio of therapeutics/diagnostics Near-term commercial opportunity with late-stage program in ultra-orphan indication RELISTOR Oral PDUFA Date: July 19, 2016; triggers $50M milestone payment PSMA-targeted pipeline: potential to transform clinical practice in prostate cancer Strong financial position: $65.7M as of 3/31/2016 AZEDRA 1404 PyL TM PSMA ADC 1095 RELISTOR Pivotal trial More sensitive in Potential to Demonstrated Potent activity in SC Formulation under SPA for detecting cancer detect minimal activity, tolerability advanced cancer, Marketed by Valeant Pheochromocytoma vs. MRI in Phase 2 levels of cancer, in Phase 2 MSKCC to start in US for OIC and Paraganglioma sites of relapse Phase 1 3
4 PIPELINE Preclinical Phase 1 Phase 2 Pivotal/ Phase 3 Approved ULTRA-ORPHAN THERANOSTIC AZEDRA Theranostic Pheochromocytoma REGISTRATIONAL PHASE 2 UNDER SPA PROSTATE CANCER THERANOSTICS EXINI Bone BSI Bone Scan Index Software APPROVED FOR USE IN EU, JAPAN AND US (not currently available in US) 1404 PSMA-targeted SPECT Imaging Agent PSMA ADC Therapeutic Prostate Cancer PyL PSMA-targeted PET Imaging Agent 1095 Small Molecule Therapeutic PSMA Antibody Radiolabeled with Alpha Emitter Licensed to Bayer OIC Treatment RELISTOR SC Opioid-induced constipation : 4 RELISTOR ORAL Opioid-induced Constipation PDUFA DATE: July 19, 2016
5 AZEDRA: ULTRA-ORPHAN THERANOSTIC Adrenal Glands Novel, targeted radiotherapy candidate Phase 2b pivotal trial under SPA for malignant pheochromocytomas and paragangliomas Enrollment completed Top-line data expected late 2016/early 2017 FDA Breakthrough Therapy Designation and Fast Track Status Pheochromocytoma and paraganglioma are rare tumors found primarily in the adrenal glands Results in the release of excess hormones that control heart rate, metabolism and blood pressure Left untreated, tumors most often lead to death due to high blood pressure, heart failure, stroke or metastatic disease No currently approved therapies in the U.S. Potential utility in treating neuroblastoma and other neuroendocrine diseases 5 Plan to commercialize independently
6 PIVOTAL PHASE 2 TRIAL UNDER SPA Study Design Data* Number of patients 58 planned; 68 enrolled 41 received therapeutic dose(s) Dosing regimen Patients receive 2 therapy doses, 3 months apart 7 patients have received 1 dose 34 have received 2 doses Primary endpoint under SPA Secondary objectives 25% of study patients respond (>50% reduction in anti-hypertensive medication) Proportion of subjects with PR by RECIST criteria 32% responded n=13 14/34 (41%) Next Steps Top-line data late 2016 / early *Data from patients dosed by MIP prior to acquisition by Progenics
7 AZEDRA Phase 2 Tumor Response Rates 85% had measurable decrease in tumor size * Response Rates Measured by RECIST Best change in sum of target lesion diameters from baseline at any time point Best change (%) in sum of target lesion diameters from baseline at any time point Yes = achieve reduction of antihypertensive medication by at least 50% for 6 months. No = did not achieve reduction of antihypertensive medication by at least 50% for 6months. 7 *Data from patients dosed by MIP prior to acquisition by Progenics
8 AZEDRA Advancing Toward Market Upcoming Milestones Targeted Market Late 2016/Early 2017 Topline results from pivotal Phase 2b trial 1H 2017 Anticipated submission of NDA to FDA Ultra-Orphan - Less than 1,000 cases of pheochromocytoma and paraganglioma diagnosed in the U.S. each year 25-30% of cases are genetic U.S. market reachable with a small specialty salesforce targeting major centers where these rare tumors are treated 8
9 PROSTATE CANCER THERANOSTICS EXINI Bone BSI Bone Scan Index Software 1404 SPECT/CT PSMA-targeted Imaging Agent PyL PET/CT PSMA-targeted Imaging Agent 1095 PSMA-targeted Small Molecule Therapeutic PSMA Antibody Radiolabeled with Alpha Emitter Licensed to Bayer 9
10 MULTIPLE OPPORTUNITIES TO USE PSMA TARGETED IMAGING AGENTS POINT IN TREATMENT PATH PRODUCT CLINICAL NEED Initial Diagnosis (after elevated PSA) 1404 (SPECT/CT) Localize lesions for targeting biopsy; avoid over/under diagnosis associated with biopsy Active Surveillance (initial diagnosis low risk cancer) 1404 (SPECT/CT) Lower morbidity than biopsy and higher specificity than PSA Primary Staging 1404 (SPECT/CT) PyL (PET/CT) PSMA identifies lymph node and visceral lesions in addition to bone mets Treatment Planning and Monitoring 1404 (SPECT/CT) PyL (PET/CT) Improve accuracy of surgery and radical radiotherapy; open curative window for treatment of metastases Detecting Recurrent Disease PyL (PET/CT) Images lesions that are not detected by current technologies 10
11 40-50% of men are now choosing Active Surveillance 1404 has the potential to enable Active Surveillance 11
12 1404 PSMA-TARGETED IMAGING AGENT SPECT radiopharmaceutical product candidate targeting PSMA In Phase 3 with interim results expected 2H 2016 Positive Phase 2 data: higher detection rate vs. MRI SPECT/CT 1404 scan showing primary prostate cancer Potential to transform clinical practice with improved detection and monitoring 12
13 DETECTING PROSTATE CANCER IN THE GLAND - MRI Gleason 4+5 Lesion Prostate 13
14 DETECTING PROSTATE CANCER IN THE GLAND 1404 SPECT/CT Histopathology 14
15 1404: PHASE 2 RESULTS Detected prostate cancer in the prostate gland with a high degree of sensitivity (94%) 1404 readers detected more prostate cancer in the prostate gland (94%) than MRI (86%) T:B quantitative and semiquantitative methods of assessing gland/lobe uptake show highly significant correlation with Gleason score (p<0.0001) Uptake of 1404 in the prostate gland is significantly lower in treated patients (p<0.0001) 15
16 1404 PHASE 3 STUDY DESIGN Patient Population Biopsy confirmed low-grade prostate cancer who are eligible for active surveillance but decided to have a radical prostatectomy N Primary Endpoint ~450 evaluable patients; interim analysis for futility or need for sample size re-estimation performed after approximately one-third of the patients have been treated (expected 2H16) Specificity of 1404 to identify patients without clinically significant prostate cancer Sensitivity of 1404 to identify patients with clinically significant prostate cancer Secondary Endpoint Safety and tolerability; Location of disease 1404 Study Overview: Biopsy Confirmed Gleason Score m Tc-MIP Dosing SPECT/ CT Imaging Prostatectomy Histopathology of prostate 16
17 PyL: PET/CT IMAGING AGENT PET Radiopharmaceutical product candidate targeting PSMA In-licensed from Johns Hopkins University PSMA Targeting Enables visualization of both bone and soft tissue metastases Highly specific to prostate cancer cells, not confounded by degenerative or inflammatory conditions Scanned in >100 patients to date 17
18 PYL: PET/CT IMAGING AGENT Pilot Study Data: Investigator Sponsored Studies Men with Elevated PSA Following Radical Prostatectomy 1 N=30 Very high standardized uptake values (SUV) even in small lesions Men with Metastatic N=8 Identified more lesions than conventional imaging Prostate Cancer 2 Proof of Concept N=9 Can detect lesions as small as 3mm Study 3 Well tolerated with no SAEs to date; few mild AEs Next Steps Several clinical trials, including two phase 2 studies 1 Gorin, M., et al., AUA Rowe, S. et al, Mol Imaging Biol April Szabo Z, et al. Mol Imaging Biol. April
19 1095: PSMA TARGETED SMALL MOLECULE THERANOSTIC FOR PROSTATE Targeted small molecule radiotherapeutic that selectively binds to PSMA 100 * Best PSA Response in 25 patients Delivers lethal dose of radiation directly to prostate cancer cells with minimal impact on surrounding healthy tissue Markedly reduced PSA levels in a heavily pretreated group of 25 evaluable patients, and reduced bone pain in German compassionate use study in advanced prostate cancer % CHANGE IN PSA 0 Primary study site for Phase 1: Memorial Sloan Kettering, the Coordinating Center for the Prostate Cancer Clinical Trials Consortium (PCCTC) PATIENT NUMBER Zechmann CM, et al. Eur J Nucl Med Mol Imaging
20 EXINI Located in Lund, Sweden Capabilities Sophisticated software that assists physicians and patients in visualizing, understanding, targeting and treating cancer Successful development and commercialization of software products based on medical image analysis and machine learning Relationships with key European partners, clinicians, and researchers to support late-stage pipeline EXINI Bone BSI Quantifies tumor burden of the skeleton and calculates the Bone Scan Index BSI outcome not affected by human reader variability Reduced turnaround time Observer-independent FDA 510(k) clearance and CE-marked 20
21 LEVERAGING OUR PSMA ANTIBODY TECHNOLOGY April 2016 Granted Bayer worldwide rights to develop and commercialize products combining our PSMA Antibody Technology exclusively with Bayer s alpha-emitting radionuclides Upfront payment of $4M million Up to an additional $49M in potential clinical and regulatory development milestones Potential net sales milestone payments up to an aggregate total of $130M Single digit royalties on net sales 21
22 RELISTOR ORAL (July 19, 2016 PDUFA) An estimated 3% of the adults in the US are receiving long- term opioid therapy 41% of those patients, or approximately 3.7 million patients, develop Opioid Induced Constipation (OIC) The prescription market for OIC is growing rapidly now that there is an oral option In our phase III program, Relistor oral significantly increased the percentage of patients with a rescue-free bowel movement (RFBM) within 4 hours 22 Spencer Dorn, et al. American Journal of GASTROENTEROLOGY 2014
23 RELISTOR Economics of Valeant Collaboration Marketed by Valeant Valeant creating pain-specific sales force to detail RELISTOR Subcutaneous formulation approved for patients with insufficient response to laxatives with: OIC in advanced illness who are receiving palliative care OIC in chronic, non-cancer pain All patients with OIC (Europe) NDA for RELISTOR Oral submitted June 2015, PDUFA July 19, 2016 $50M licensing milestone upon U.S. approval of RELISTOR Oral Royalty scale based on WW net sales, ranging from 15%-19% Commercial licensing milestones totaling up to $200M, including $10M on first $100M in sales Entitled to receive 60% of revenues received by Valeant from ex-u.s. sub-licensees (SOBI) 23
24 2016 PRIORITIES Top -Line Data for Pivotal Phase 2 AZEDRA Trial Late 2016/Early 2017 Interim Analysis for Pivotal Phase Trial Initiate Phase 2 Trial for PyL Initiate Phase 1 Trial for 1095 Commercialize EXINI Bone BSI in the US RELISTOR Oral July19, 2016 PDUFA AZEDRA 1404 PyL PSMA ADC 1095 RELISTOR Pivotal trial More sensitive in Potential to Demonstrated Potent activity in SC Formulation under SPA for detecting cancer detect minimal activity, tolerability advanced cancer, Marketed by Valeant Pheochromocytoma vs. MRI in Phase 2 levels of cancer, in Phase 2 MSKCC to start in US for OIC and Paraganglioma sites of relapse Phase 1 24
25 Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies 2016
Targeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker CEO Jefferies Healthcare Conference June 8, 2017 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future
More informationLeading Development of Radiopharmaceuticals to Detect and Treat Cancer
Leading Development of Radiopharmaceuticals to Detect and Treat Cancer October 2018 All trademarks, registered or otherwise, are the property of their respective owner. 2018 Progenics Pharmaceuticals,
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationPhase 2b/3 Topline Trial Results
Phase 2b/3 Topline Trial Results RP-G28 For the Treatment of Lactose Intolerance March 2017 Forward - Looking Statement To the extent that statements contained in this presentation are not descriptions
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationASCEND Phase 2 Trial of AXS-05 in MDD Topline Results Conference Call
NASDAQ: AXSM ASCEND Phase 2 Trial of in MDD Topline Results Conference Call January 7, 2019 Overview in MDD ASCEND Phase 2 Trial Topline Results Introduction Mark Jacobson, Senior Vice President, Operations
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationCompany Presentation. September 2018
Company Presentation September 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationTHE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016
THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 1 BAVARIAN NORDIC INVESTOR & ANALYST UPDATE & RECEPTION Welcome and Introduction to Bavarian Nordic s Cancer immunotherapy Programs Paul Chaplin,
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationFebruary 20, 2019 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES
February 20, 209 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES Forward-Looking Statements This presentation contains certain forward-looking statements that are made pursuant
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationAbout X-Linked Hypophosphatemia (XLH)
Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal
More informationINTERIM RESULTS AS OF MARCH 31, 2018
INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationCorporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO
NASDAQ: DRNA Corporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO Forward looking statements This information may contain projections
More informationSucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference
Sucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference June 3, 2015 Peter Greenleaf Chief Executive Officer Forward-Looking Statements This presentation contains "forward-looking statements"
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference June 7, 2016 NASDAQ: CHMA Forward-Looking Statements These slides contain forward-looking statements and information. The use of words such as may, might, will, should,
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationBuilding a Stroke Portfolio. June 28, 2018
Building a Stroke Portfolio June 28, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: the potential benefits, safety and efficacy
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C
ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C OCTOBER 11, 2017 NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationPLEO-CMT Top-line Results. Presentation October 16, 2018
PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this
More informationProsensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, Hans Schikan, CEO
Prosensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, 2014 Hans Schikan, CEO Forward-Looking Statements This presentation may contain statements that constitute forward-looking
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More information- Amendment accelerates anticipated PROSPER top-line results by two years -
Pfizer Contacts: For Media Dean Mastrojohn (212) 733-6944 dean.mastrojohn@pfizer.com For Investors Ryan Crowe (212) 733-8160 ryan.crowe@pfizer.com Astellas Contact: For Media Tyler Marciniak (847) 736-7145
More informationAxsome Therapeutics, Inc. AXS-05 R&D Day CNS Pipeline Overview
AXS-05 R&D Day April 24, 2018 Axsome Therapeutics, Inc. AXS-05 R&D Day CNS Pipeline Overview Herriot Tabuteau, MD Chief Executive Officer Axsome Therapeutics, Inc. New York City 3 Forward-Looking Statements
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationConventional therapy n=32. RGI-C Score (Primary Endpoint) LS Mean* (0.83, 1.45) P< Substantial healing, % patients (RGI-C +2.
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationPfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More information